Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.

This article summarizes the discussions of a colloquium on oral GPIIb/IIIa receptor blockers in London, U.K. 4 and 5 May 2000, which was convened under the auspices of the European Society of Cardiology. The participants of the meeting are listed in the appendix. Financial support for the meeting was obtained from the European Society of Cardiology and the companies listed in the Appendix. Introduction

[1]  J. Faul,et al.  Role of Extracellular Ionized Calcium in the In Vitro Assessment of GPIIb/IIIa Receptor Antagonists , 2004, Journal of Thrombosis and Thrombolysis.

[2]  V. Hasselblad,et al.  Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. , 2001, JAMA.

[3]  Deepak L. Bhatt,et al.  Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists: A Meta-Analysis of Phase III Multicenter Randomized Trials , 2001, Circulation.

[4]  J. Deckers,et al.  Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. , 2000, European heart journal.

[5]  P. Théroux,et al.  Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. , 2000, Journal of the American College of Cardiology.

[6]  R. Califf,et al.  Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. , 2000, Circulation.

[7]  A. Skene,et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.

[8]  E. Braunwald,et al.  First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. , 2000, American heart journal.

[9]  R. Califf,et al.  Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. , 2000, Journal of the American College of Cardiology.

[10]  P Serruys,et al.  Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. , 2000, The New England journal of medicine.

[11]  M. Hadamitzky,et al.  Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. , 2000, Journal of the American College of Cardiology.

[12]  M. Verstraete,et al.  Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. , 2000, Circulation.

[13]  C. Cannon,et al.  Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. , 2000, The American journal of cardiology.

[14]  R. Califf,et al.  Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial , 2000, The Lancet.

[15]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. , 1999, Circulation.

[16]  S. Steinhubl,et al.  Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. , 1999, Circulation.

[17]  R. Wilcox,et al.  A Whole Blood Assay of Inhibition of Platelet Aggregation by Glycoprotein IIb/IIIa Antagonists: Comparison with other Aggregation Methodologies , 1999, Thrombosis and Haemostasis.

[18]  G. Dangas,et al.  Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. , 1999, American heart journal.

[19]  S. Steinhubl,et al.  Rapid platelet-function assay: an automated and quantitative cartridge-based method. , 1999, Circulation.

[20]  Eric J Topol,et al.  Platelet GPIIb-IIIa blockers , 1999, The Lancet.

[21]  David P Miller,et al.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. , 1998, Circulation.

[22]  C. Bode,et al.  Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors , 1998 .

[23]  M. Simoons,et al.  Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. , 1998, European heart journal.

[24]  E. Ohman,et al.  Relation between inhibition of platelet aggregation and clinical outcomes. , 1998, American heart journal.

[25]  E. Topol,et al.  Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. , 1998, Circulation.

[26]  J. Burchenal,et al.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.

[27]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[28]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[29]  E. Braunwald,et al.  Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. , 1998, Circulation.

[30]  Gebhardt,et al.  International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina , 1998 .

[31]  A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. , 1998, The New England journal of medicine.

[32]  J. Burchenal,et al.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.

[33]  W. V. Mieghem,et al.  International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. , 1998, Circulation.

[34]  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.

[35]  A. Zeiher,et al.  Platelet glycoprotein Illa polymorphisms and risk of coronary stent thrombosis , 1997, The Lancet.

[36]  T. Investigators.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. , 1997, Circulation.

[37]  L. Jennings,et al.  Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. , 1997, Circulation.

[38]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[39]  D. Praticò,et al.  Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. , 1997, The Journal of pharmacology and experimental therapeutics.

[40]  Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II , 1997, The Lancet.

[41]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[42]  B. Coller,et al.  Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. , 1997, Circulation.

[43]  P. Ridker,et al.  PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis , 1997, The Lancet.

[44]  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. , 1997, Lancet.

[45]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[46]  H. Hemker,et al.  Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". , 1996, The Journal of clinical investigation.

[47]  J. Weiss,et al.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. , 1996, The New England journal of medicine.

[48]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[49]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[50]  Anticoagulants in the Secondary Prevention of Events in Coronary Group.  Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction , 1994, The Lancet.

[51]  S. Cobbe.  Thrombolysis in myocardial infarction , 1994, BMJ.

[52]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[53]  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. , 1994, BMJ.

[54]  P Smith,et al.  The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.

[55]  R. Jordan,et al.  Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. , 1989, Circulation.

[56]  K. McPherson,et al.  Secondary prevention of vascular disease by prolonged antiplatelet treatment , 1988, British medical journal.